Albireo Pharma, Inc. ALBO Cash Flow

Albireo pharma, inc. (ALBO)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11
Cash flows from operating activities:
Net loss
-31,488	-7,522	-21,910	-16,628	-16,657	-15,864	-14,025	-14,603	-1,619	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-6,671	-11,220	-4,030	2,139	-3,239	-3,215	-3,232	-6,462	-4,356	-4,687	-2,286	-3,205	-6,197	-2,443	-815	-9,631	-5,220	-3,669	-5,879	-6,050	-4,317	-4,501
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of liability related to sale of future royalties
2,040	2,181	2,104	2,070	2,005	2,095	2,852	1,021	1,007	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of debt discount and amortization of issuance costs
-	-	-	-	-	-	-	-	-	-224	86	130	171	221	287	280	277	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
39	38	39	39	11	12	11	-31	53	12	10	8	5	3	4	3	4	30	-14	47	62	102	141	152	154	156	157	158	159	167	170	173	188	194
Change in fair value of financial instruments
-	-	-	-	-	-	-	-	-	0	0	584	-333	-523	-84	709	-89	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Founder's compensation contributed to capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Stock-based compensation expense
2,381	1,880	1,826	2,049	1,823	1,678	1,624	1,056	1,188	839	810	646	1,405	944	139	-355	410	111	217	226	230	195	139	136	214	295	322	326	345	545	317	332	337	842
Unrealized foreign exchange loss
-	-	-	-	-	-	-	-5,518	-1,200	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Foreign currency adjustments
-6,544	-	-	-	-3,441	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Trade receivables
-	-	-	-	-	-	-	-	-	-11	10	-1	-26	18	-16	-1,682	434	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation for non-employees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Loss on settlement of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Write-off of capitalized patent expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	38	0	0
Write-off of loan to related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Adjustments to fair value of common stock warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	6	-4	0	2	178	119	166	546	1,399	1,547	-425	2,586	3,536	-4,431	-116	2,228	-156	-1,355	146	-145
Prepaid expenses and other current assets
-1,283	4,470	199	1,336	326	982	-255	1,778	-401	709	-148	-86	-8	513	-1	-195	-103	403	-119	-241	-270	579	-83	-216	-115	461	-424	-265	-163	821	-121	-211	-200	421
Other receivables
-	-	-	-	-	-	-	-	738	1	46	-8	300	149	-137	114	16	-	-	-	-	-	-	-	-	-	0	0	1	-9	9	0	0	-1
Other assets
-135	122	-176	-26	440	-24	-25	-22	-332	260	-27	-65	77	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income taxes receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	-	-	-	0	-	-	-	-	-12	-16	0	0	0	-1	0	0
Grant receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-227	20	110	71	1	-4	-256	196	88	0	0	0
Accounts payable
2,233	1,512	-542	869	-1,262	-	-	-	-	-	-	-	-	-	-317	352	-220	-86	232	-157	-89	263	-202	-267	-1,147	1,542	6	-72	-817	844	105	66	-37	-71
Trade payables
-	-	-	-	-	-	-	-	924	-202	185	-54	334	-294	-55	-1,531	716	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income taxes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-16	8	8	-	13	1	2	0	-7	4	-72	0	-22	4	-8	26	-22	-8	2
Accrued expenses
-6,987	-1,698	-125	-653	-1,619	2,370	707	-642	-1,581	1,539	620	-241	-3,623	1,606	-507	1,972	143	-326	-	562	500	-191	-146	382	-35	-904	-154	623	-1,382	666	-358	10	80	140
Other current and long-term liabilities
24	112	-184	507	-499	-38	-230	139	-69	163	81	169	-140	159	8	-39	16	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total adjustments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-763	543	2,108	-677	-333	813	808	-754	-1,160	-951	-380	-2,101	-2,770	5,729	-1,157	-1,022	440	2,164	614	832
Net cash provided by (used in) operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-8,529	-6,460	-3,916	3,933	-2,341	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-23,796	-12,400	-14,006	-12,990	-13,523	-9,996	-10,287	-7,617	1,098	-	-	-	-	-	-	-2,552	-3,760	-3,892	-	-5,649	-3,548	-5,441	-3,446	-4,156	-6,577	-4,544	-3,585	-3,902	-6,377	-4,691	-5,439	-3,886	-3,703	-3,669
Cash flows from investing activities:
Purchase of property, plant and equipment
-	-	-	-	-	0	0	14	47	3	41	51	95	0	0	0	3	-	-	-	-	-	17	0	26	6	31	0	0	87	59	-6	6	0
Deferred public offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Stockholder contribution
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Proceeds from issuance of Series C preference shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Purchase of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Sale of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Capitalized intellectual properties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Loan to related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Net cash used in investing activities
-	-	-	-	-	0	14	-14	-47	-	-	-	-	-	-	-	-	-	-	-	-	-	-17	0	-26	-6	-31	0	0	-87	-59	6	-6	0
Cash flows from financing activities:
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-95	25,483	0	0	-3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrants exercised
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Net proceeds from employee stock purchase plan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	31	0	10	0	5	0	10	0	24	0	6	0	6	1	20
Net proceeds from ATM facility
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	1,491	100	3,081	-55	0	0	-	-	-	-	-	-	-	-
Net proceeds from equity line
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	203	469	490	0	0	0	-	-	-	-	-	-	-	-
Net proceeds from sale of unregistered common stock - private placement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-143	8,730	0	0
Proceeds from issuance of common stock, net of issuance costs
42,999	-	-	-	-	11	-10	-1	94,150	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	955	18,284	0	0	0	0	0	0
Royalty monetization
-	-	-	-	-	0	0	0	44,525	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-21	-	0	0	0	-	-	-	-	-	-	-	-	1,000	500	-1,500	0
Proceeds from exercise of options
94	1,251	78	110	1,290	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	75	0	0	0	0	0	0
Payments of principal on borrowings
-	-	-	-	-	-	-	-	-	896	511	859	789	730	718	386	323	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from bridge financing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Net cash provided by financing activities
43,093	1,252	78	20,884	1,290	11	242	254	138,675	-	-	-	-	-	-	0	0	-21	-	32,280	1,594	579	3,571	-50	48	10	1,015	18,383	0	6	857	17,727	-1,499	20
Effect of exchange rate changes on cash and cash equivalents
-625	342	-1,014	-102	-1,313	268	405	-2,311	-41	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
18,672	-10,823	-15,056	7,383	-13,546	-9,717	-9,626	-9,688	139,685	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-789	8,960	-713	-312	-323	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	694	-375	233	94	217	-41	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	42,455	-9,788	28,216	-4,535	3,838	-2,708	-3,913	-3,510	26,602	-1,973	-4,862	108	-4,206	-6,555	-4,540	-2,601	14,481	-6,377	-4,772	-4,641	13,847	-5,208	-3,649
Supplemental disclosures of cash and non-cash activities:
Right of use assets and lease obligations recorded upon amended lease agreements
-	-	-	-	1,205	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lease liability
-	-	-	-	1,190	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	0	0	0	0	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	78	-4	171	84	199	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-3	13	9	24	2	0	0	6	5	12	2	0	0	0	12	0	14	0	6
Conversion of convertible preferred stock to common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	19	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Warrants issued in connection with registered direct offering
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Warrants issued in connection with unregistered common stock private placement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	4,832	0	0
Settlement of debt with Series B preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Accrued expenses settled with Series B preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Deemed dividend - warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Accretion of fair value of beneficial charge on preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Conversion of convertible preferred stock to common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Issuance of restricted stock units to settle accrued bonus
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	584	0	0	0